TP53 and neoplasm: To evaluate the in vivo therapeutic potential of combination therapy with Ad-p53 DCs and OBP-702 against p53-mutant CC tumors, we used subcutaneous murine CC tumor models with p53-mutant MC38 cells (Fig. 6E).